Continuing Medical Education
Accreditation Statement
The American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Credit Designation Statement
AACR has designated this live activity for a maximum of 21.00 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Claiming (CME) Credit
Physicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the online CME Request for Credit Survey by August 4, 2024. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 21.00 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
To receive ABIM MOC, participants must request MOC in the CME Request for Credit Survey and complete all questions. Once these steps are completed, AACR will submit your completion information via the ACCME’s Program and Activity Reporting System for the purpose of granting MOC points.
Statement of Educational Need, Target Audience, and Learning Objectives
According to the latest data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) Program; Non-Hodgkin Lymphoma (NHL) is the seventh most common cancer in the United States with an estimated 80,550 new cases diagnosed in 2023. An estimated 20,180 individuals died from NHL in 2023. Although lower in number than NHL, an estimated 8,830 new cases of Hodgkin Lymphoma (HL) were diagnosed in 2023, with an estimated 900 deaths.
Dramatic increases in the five-year survival rates for both NHL and HL over the past fifty years have resulted in both NHL and HL being considered as success stories in terms of cancer survival. However, additional research and collaboration is needed in the early detection of these diseases and in the treatment and diagnosis of the lymphoma to reduce the number of new cases which has remained relatively flat.
The AACR, in close collaboration with the ICML, has developed a program that focuses specifically on providing a forum for interactive discussion and brainstorming between basic scientists, translational researchers, clinical investigators, and computational biologists to debate how recent advances and emerging areas of research can transform clinical care.
The Chair and Cochairs created a program that addresses specific questions that span the basic science to clinical care continuum and purposely extended the time for discussion to encourage interaction with the audience, but also among the speakers presenting their latest research. The Chair and Cochairs specifically avoided sessions dedicated to one subtype of lymphoma to encourage interaction and participation from all stakeholders.
The lymphoma field is advancing rapidly thanks to the full sequencing of the lymphoma genome, new mechanistic data explaining how mutations work, development of targeted therapies, recognition of “pre-lymphoma” states as potential risk factors, and the advent of immunotherapy and the unique features of immune tumors.
The research being presented at this meeting will address the need for more effective and earlier detection strategies, provide insights into new clinical decision-making tools, and discuss recent advances in both basic science and clinical approaches across several subtypes of lymphoma. The program was designed to take advances in basic research areas and discuss how those are being applied, or have the potential to be applied for the betterment of patients in the clinic. Physician-scientists and clinicians will leave this program with new knowledge in the fields of CAR T-cells, chemotherapy-free management and treatment, clonal precursors and transformation, epigenetics genomics, germinal center biology, immune synapse, lymphomagenesis, microenvironment, premalignant processes, signaling, T-cell engagers, and tumor immunology.
After participating in this CME activity, physicians should be able to:
- Articulate the impact of age and ethnicity on lymphoma etiology and outcomes for patients.
- Assess the potential impact of new and emerging chemotherapy-free treatment approaches in lymphoma.
- Explain the role of germinal center biology in lymphomagenesis.
- Provide an overview of new CAR T-cell therapy approaches for lymphoma.
Disclosure Statement
It is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, AACR will provide information that Scientific Program Committee members and speakers have disclosed all financial relationships they have with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products or services used by or on patients. All of the relevant financial relationships for these individuals have been mitigated.
Acknowledgment of Financial or Other Support
The AACR gratefully acknowledges the following commercial supporters for their Professional Educational Grants:
- Novartis
Questions about CME?
Please read our frequently asked questions. If you still have questions, contact the Office of CME at (215) 440-9300 or [email protected].